Clinical trial

The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation

A. Agrawal, L. A. Houghton, J. Morris, B. Reilly, D. Guyonnet, N. Goupil Feuillerat, A. Schlumberger, S. Jakob, P. J. Whorwell

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

Background: A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit. Aim: To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation. Methods: A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients. Results: Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference - 39%, 95% CI (-78, -5); P = 0.02] and a trend towards reduced mean distension during the day [-1.52 cm (-3.33, 0.39); P = 0.096]. An acceleration of orocaecal [-1.2 h (-2.3,0); P = 0.049] as well as colonic [-12.2 h (-22.8, -1.6); P = 0.026] transit was observed and overall symptom severity [-0.5 (-1.0, -0.05); P = 0.032] also improved. Conclusions: This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.

Original languageEnglish (US)
Pages (from-to)104-114
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume29
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Cultured Milk Products
Gastrointestinal Transit
Irritable Bowel Syndrome
Constipation
Clinical Trials
Probiotics
Population
Bifidobacterium animalis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical trial : The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. / Agrawal, A.; Houghton, L. A.; Morris, J.; Reilly, B.; Guyonnet, D.; Goupil Feuillerat, N.; Schlumberger, A.; Jakob, S.; Whorwell, P. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 29, No. 1, 01.2009, p. 104-114.

Research output: Contribution to journalArticle

Agrawal, A. ; Houghton, L. A. ; Morris, J. ; Reilly, B. ; Guyonnet, D. ; Goupil Feuillerat, N. ; Schlumberger, A. ; Jakob, S. ; Whorwell, P. J. / Clinical trial : The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. In: Alimentary Pharmacology and Therapeutics. 2009 ; Vol. 29, No. 1. pp. 104-114.
@article{00563e01b7a04c89b960a4cf588f4730,
title = "Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation",
abstract = "Background: A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit. Aim: To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation. Methods: A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients. Results: Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference - 39{\%}, 95{\%} CI (-78, -5); P = 0.02] and a trend towards reduced mean distension during the day [-1.52 cm (-3.33, 0.39); P = 0.096]. An acceleration of orocaecal [-1.2 h (-2.3,0); P = 0.049] as well as colonic [-12.2 h (-22.8, -1.6); P = 0.026] transit was observed and overall symptom severity [-0.5 (-1.0, -0.05); P = 0.032] also improved. Conclusions: This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.",
author = "A. Agrawal and Houghton, {L. A.} and J. Morris and B. Reilly and D. Guyonnet and {Goupil Feuillerat}, N. and A. Schlumberger and S. Jakob and Whorwell, {P. J.}",
year = "2009",
month = "1",
doi = "10.1111/j.1365-2036.2008.03853.x",
language = "English (US)",
volume = "29",
pages = "104--114",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical trial

T2 - The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation

AU - Agrawal, A.

AU - Houghton, L. A.

AU - Morris, J.

AU - Reilly, B.

AU - Guyonnet, D.

AU - Goupil Feuillerat, N.

AU - Schlumberger, A.

AU - Jakob, S.

AU - Whorwell, P. J.

PY - 2009/1

Y1 - 2009/1

N2 - Background: A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit. Aim: To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation. Methods: A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients. Results: Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference - 39%, 95% CI (-78, -5); P = 0.02] and a trend towards reduced mean distension during the day [-1.52 cm (-3.33, 0.39); P = 0.096]. An acceleration of orocaecal [-1.2 h (-2.3,0); P = 0.049] as well as colonic [-12.2 h (-22.8, -1.6); P = 0.026] transit was observed and overall symptom severity [-0.5 (-1.0, -0.05); P = 0.032] also improved. Conclusions: This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.

AB - Background: A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit. Aim: To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation. Methods: A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients. Results: Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference - 39%, 95% CI (-78, -5); P = 0.02] and a trend towards reduced mean distension during the day [-1.52 cm (-3.33, 0.39); P = 0.096]. An acceleration of orocaecal [-1.2 h (-2.3,0); P = 0.049] as well as colonic [-12.2 h (-22.8, -1.6); P = 0.026] transit was observed and overall symptom severity [-0.5 (-1.0, -0.05); P = 0.032] also improved. Conclusions: This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.

UR - http://www.scopus.com/inward/record.url?scp=57649208538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649208538&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2008.03853.x

DO - 10.1111/j.1365-2036.2008.03853.x

M3 - Article

VL - 29

SP - 104

EP - 114

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -